EA
NVS icon

Everpar Advisors’s Novartis NVS Stock Holding History

Everpar Advisors’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
2,326
+203
+10% +$30.4K 0.1% 188
2026
Q1 		$324K Buy
2,123
+137
+7% +$21K 0.11% 192
2025
Q4 		$274K Buy
+1,986
New +$260K 0.1% 212

Other funds holding NVS

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
SI
Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MGIA
Matthew Goff Investment Advisor Houston, Texas $593M AUM 28.9% 1-Year Est. Return
ERP
Eldred Rock Partners San Antonio, Texas $465M AUM 48.86% 1-Year Est. Return
CCM
Cohen Capital Management Corte Madera, California $735M AUM 36.88% 1-Year Est. Return

Everpar Advisors's NVS Position: Q2 2026 in Review

Everpar Advisors increased its Novartis (NVS) stake by 9.6% in Q2 2026, buying an estimated $30.4K and bringing the position to 2,326 shares worth $365K. The position accounts for 0.1% of the portfolio, ranked #188.

Everpar Advisors first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Everpar Advisors held 2,326 shares of Novartis worth $365K as of Q2 2026.
  • Everpar Advisors bought 203 Novartis shares in Q2 2026, an estimated $30.4K.
  • Novartis made up 0.1% of Everpar Advisors's portfolio in Q2 2026, its #188 holding.
  • Everpar Advisors first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.